• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients.癌症患者接种新型冠状病毒mRNA加强疫苗后的血清转化
Eur J Cancer. 2022 May;167:175-176. doi: 10.1016/j.ejca.2022.02.032. Epub 2022 Mar 15.
2
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. 异源加强免疫与同源加强免疫在原发性 mRNA 疫苗接种后未发生 SARS-CoV-2 抗体血清转化的免疫抑制患者中的效果比较：一项随机对照试验。
Ann Rheum Dis. 2022 May;81(5):687-694. doi: 10.1136/annrheumdis-2021-221558. Epub 2022 Jan 13.
3
BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.BNT162b2信使核糖核酸新冠疫苗加强针可使先前两剂疫苗接种无反应的B细胞非霍奇金淋巴瘤患者发生血清转化。
Br J Haematol. 2022 Mar;196(6):1329-1333. doi: 10.1111/bjh.18029. Epub 2022 Jan 25.
4
Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study.中重度银屑病患者接受系统生物制剂治疗后抗 SARS-CoV-2 mRNA 疫苗接种的血清转化率：前瞻性观察队列研究。
Dermatol Ther. 2022 May;35(5):e15408. doi: 10.1111/dth.15408. Epub 2022 Mar 5.
5
Immediate reactions after mRNA SARS-CoV-2 vaccination.新型冠状病毒mRNA疫苗接种后的即时反应。
CMAJ. 2021 Dec 6;193(48):E1842. doi: 10.1503/cmaj.211581. Epub 2021 Nov 12.
6
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.新冠疫苗在免疫功能低下患者中的有效性：系统评价和荟萃分析。
BMJ. 2022 Mar 2;376:e068632. doi: 10.1136/bmj-2021-068632.
7
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.接受 BNT162b2 抗 SARS-CoV-2 疫苗第三剂后的免疫原性和安全性在积极治疗中的实体瘤患者：一项前瞻性队列研究。
ESMO Open. 2022 Apr;7(2):100458. doi: 10.1016/j.esmoop.2022.100458. Epub 2022 Mar 11.
8
Patients with Solid Tumors Seroconvert after SARS-CoV-2 mRNA Vaccine.实体瘤患者在接种 SARS-CoV-2 mRNA 疫苗后血清转化。
Cancer Discov. 2021 Sep;11(9):2122. doi: 10.1158/2159-8290.CD-RW2021-099. Epub 2021 Jul 16.
9
Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over.12岁及以上囊性纤维化患者中基于mRNA的SARS-CoV-2疫苗的安全性。
J Cyst Fibros. 2022 May;21(3):e173-e175. doi: 10.1016/j.jcf.2022.02.009. Epub 2022 Feb 16.
10
Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment. Role of the Research Nurse.正在接受积极治疗的癌症患者对 SARS-CoV-2 mRNA BNT162b2 疫苗不良血清转化率和不良事件的预测因素。研究护士的作用。
Prof Inferm. 2021 Oct-Dec;74(4):261. doi: 10.7429/pi.2021.744261a.

引用本文的文献

1
Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors.化疗和/或免疫疗法对实体瘤患者对 SARS-CoV-2 mRNA-1237 疫苗的中和抗体反应的影响。
Mol Oncol. 2023 Apr;17(4):686-694. doi: 10.1002/1878-0261.13359. Epub 2022 Dec 30.
2
The national COVID-19 vaccination campaign targeting the extremely vulnerable: the Florence Medical Oncology Unit experience in patients with cancer.面向极度脆弱人群的全国 COVID-19 疫苗接种运动：佛罗伦萨医学肿瘤学组在癌症患者中的经验。
Eur J Cancer. 2022 Jul;170:149-157. doi: 10.1016/j.ejca.2022.04.008. Epub 2022 Apr 20.

本文引用的文献

1
Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment.接受癌症治疗的实体瘤患者接种 SARS-CoV-2 mRNA 疫苗后血清转换受损。
Eur J Cancer. 2022 Mar;163:16-25. doi: 10.1016/j.ejca.2021.12.006. Epub 2021 Dec 22.
2
Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer.BNT162b2 mRNA疫苗加强针在积极治疗的癌症患者中的免疫原性和安全性。
Lancet Oncol. 2022 Feb;23(2):193-195. doi: 10.1016/S1470-2045(21)00715-4. Epub 2021 Dec 23.
3
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.在癌症患者中，加强针在增强对 COVID-19 疫苗的免疫应答方面的效果。
Cancer Cell. 2022 Jan 10;40(1):3-5. doi: 10.1016/j.ccell.2021.11.006. Epub 2021 Nov 16.
4
Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe-short- And long-term Immune reSponSe evAluatioN in health Care workErs.RENAISSANCE 研究结果：BNT162b2 COVID-19 疫苗短期和长期免疫反应评估在卫生保健工作者中的反应。
Mayo Clin Proc. 2021 Dec;96(12):2966-2979. doi: 10.1016/j.mayocp.2021.08.013. Epub 2021 Aug 30.

Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients.

作者信息

Patelli Giorgio, Pani Arianna, Amatu Alessio, Scaglione Francesco, Sartore-Bianchi Andrea

机构信息

SC Oncologia Falck, Dipartimento di Ematologia, Oncologia e Medicina Molecolare, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Dipartimento di Oncologia Ed Emato-Oncologia, Università Degli Studi di Milano (La Statale), Milan, Italy.

Dipartimento di Oncologia Ed Emato-Oncologia, Università Degli Studi di Milano (La Statale), Milan, Italy; SC Analisi Chimico Cliniche e Microbiologia, Dipartimento Medicina di Laboratorio, Grande Ospedale Metropolitano Niguarda, Milan, Italy.

出版信息

Eur J Cancer. 2022 May;167:175-176. doi: 10.1016/j.ejca.2022.02.032. Epub 2022 Mar 15.

DOI:10.1016/j.ejca.2022.02.032
PMID:35370047
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8920783/
Abstract
摘要